Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-4444-8888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.72 billion
Profitability
Miscellaneous
Employees43,202
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared a Semi-Annual dividend on Friday, August 9th. Stockholders of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S announced that its board has initiated a share buyback plan on Friday, February 2nd 2018, which allows the company to repurchase shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its shares are undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Friday, August, 9th. The company reported $0.61 earnings per share for the quarter, hitting analysts' consensus estimates of $0.61. The company had revenue of $4.52 billion for the quarter, compared to the consensus estimate of $4.41 billion. Novo Nordisk A/S had a net margin of 32.16% and a return on equity of 75.16%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What price target have analysts set for NVO?
16 brokerages have issued twelve-month price objectives for Novo Nordisk A/S's shares. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $181.5760 in the next twelve months. This suggests a possible upside of 243.0% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.
What is the consensus analysts' recommendation for Novo Nordisk A/S?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.
Has Novo Nordisk A/S been receiving favorable news coverage?
Media headlines about NVO stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Novo Nordisk A/S.
Are investors shorting Novo Nordisk A/S?
Novo Nordisk A/S saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 5,018,600 shares, an increase of 36.0% from the July 31st total of 3,689,100 shares. Based on an average trading volume of 1,490,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 0.3% of the shares of the company are short sold. View Novo Nordisk A/S's Current Options Chain.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Novo Nordisk A/S own?
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
- Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
- Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
- Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
- Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.92%), Fisher Asset Management LLC (0.61%), Bank of America Corp DE (0.50%), BlackRock Inc. (0.32%), BlackRock Inc. (0.32%) and Fayez Sarofim & Co (0.18%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which institutional investors are selling Novo Nordisk A/S stock?
NVO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Grantham Mayo Van Otterloo & Co. LLC, Bank of America Corp DE, CIBC Asset Management Inc, Boston Financial Mangement LLC, Russell Investments Group Ltd. and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Novo Nordisk A/S.
Which institutional investors are buying Novo Nordisk A/S stock?
NVO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Amundi Pioneer Asset Management Inc., Jennison Associates LLC, Jennison Associates LLC, Fisher Asset Management LLC, Charles Schwab Investment Management Inc., Aperio Group LLC and Jane Street Group LLC. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $52.94.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $125.36 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.
What is Novo Nordisk A/S's official website?
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
